Investigational New Drugs 1/2008

nach oben

Inhaltsverzeichnis ( 13 Artikel )

01.02.2008 | PRECLINICAL STUDIES | Ausgabe 1/2008

INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin

Kathryn A. Mason, David Valdecanas, Nancy R. Hunter, Luka Milas

01.02.2008 | Preclinical Studies | Ausgabe 1/2008

Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits

Vinay Bhaskar, Melvin Fox, Danna Breinberg, Melanie H-L Wong, Pauline E. Wales, Susan Rhodes, Robert B. DuBridge, Vanitha Ramakrishnan

01.02.2008 | Preclinical Studies | Ausgabe 1/2008

Protein kinase C-β inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis

Arkadiusz Z. Dudek, Pawel Zwolak, Piotr Jasinski, Kaoru Terai, Nathan J. Gallus, Marna E. Ericson, Faris Farassati

01.02.2008 | Preclinical Studies | Ausgabe 1/2008

Pharmacological evaluation of C-3 modified Betulinic acid derivatives with potent anticancer activity

Praveen Rajendran, Manu Jaggi, Manoj K. Singh, Rama Mukherjee, Anand C. Burman

01.02.2008 | Phase I Studies | Ausgabe 1/2008

Phase I and pharmacokinetic study of etaracizumab (Abegrin™), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumors

Catherine Delbaldo, Eric Raymond, Karina Vera, Luz Hammershaimb, Karen Kaucic, Stéphanie Lozahic, Michel Marty, Sandrine Faivre

01.02.2008 | Phase I Studies | Ausgabe 1/2008

The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor

Kyle Holen, Leonard B. Saltz, Ellen Hollywood, Konrad Burk, Axel-Rainer Hanauske

01.02.2008 | PHASE I STUDIES | Ausgabe 1/2008

Prognostic factors among cancer patients with good performance status screened for phase I trials

Nicolas Penel, Marie Vanseymortier, Marie-Edith Bonneterre, Stéphanie Clisant, Eric Dansin, Yvette Vendel, Régis Beuscart, Jacques Bonneterre

01.02.2008 | PHASE I STUDIES | Ausgabe 1/2008

A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors

Elisabeth I. Heath, Keith Bible, Robert E. Martell, Daniel C. Adelman, Patricia M. LoRusso

01.02.2008 | PHASE II STUDIES | Ausgabe 1/2008

Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study

Emilio Esteban, Noemi Villanueva, Isabel Muñiz, Yolanda Fernández, Joaquin Fra, Maria Luque, Paula Jiménez, Beatriz Llorente, Marta Capelan, José M. Vieitez, Enrique Estrada, José M. Buesa, Angel Jiménez-Lacave

01.02.2008 | PHASE II STUDIES | Ausgabe 1/2008

Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC)

Joseph G. Kattan, Fady S. Farhat, Georges Y. Chahine, Fady L. Nasr, Walid T. Moukadem, Fariha C. Younes, Nadine J. Yazbeck, Marwan G. Ghosn, Cancer Research Group

01.02.2008 | PHASE II STUDIES | Ausgabe 1/2008

Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer

George R. Blumenschein Jr., Merrill S. Kies, Vassiliki A. Papadimitrakopoulou, Charles Lu, Ashok J. Kumar, Justin L. Ricker, Judy H. Chiao, Cong Chen, Stanley R. Frankel

01.02.2008 | Phase II Studies | Ausgabe 1/2008

A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma

Karl D. Lewis, William A. Robinson, Michael J. Millward, Alex Powell, Timothy J. Price, Damien B. Thomson, Euan T. Walpole, Andrew M. Haydon, Brian R. Creese, Kaye L. Roberts, John R. Zalcberg, Rene Gonzalez

01.02.2008 | SHORT REPORT | Ausgabe 1/2008

Pneumatosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity

Timothy R. Asmis, Ki Y. Chung, Jerrold B. Teitcher, David P. Kelsen, Manish A. Shah

Aktuelle Ausgaben

Neu im Fachgebiet Onkologie

15.04.2021 | Ösophaguskarzinom | Nachrichten

Newsletter bestellen

Bildnachweise

Mail Icon II

Springer Medizin

Investigational New Drugs

Ausgabe 1/2008

Inhaltsverzeichnis ( 13 Artikel )

INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin

Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits

Protein kinase C-β inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis

Pharmacological evaluation of C-3 modified Betulinic acid derivatives with potent anticancer activity

Phase I and pharmacokinetic study of etaracizumab (Abegrin™), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumors

The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor

Prognostic factors among cancer patients with good performance status screened for phase I trials

A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors

Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study

Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC)

Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer

A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma

Pneumatosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity

Aktuelle Ausgaben

Ausgabe 2/2021

Ausgabe 1/2021

Ausgabe 6/2020

Ausgabe 5/2020

Ausgabe 4/2020

Ausgabe 3/2020

Ausgabe 2/2020

Ausgabe 1/2020

Ausgabe 6/2019

Ausgabe 5/2019

Neu im Fachgebiet Onkologie

Adjuvantes Nivolumab "neuer Therapiestandard" beim Ösophaguskarzinom

Fortgeschrittenes Nierenzell-Ca.: Vorteil für First-Line-Lenvatinib plus Pembrolizumab

Hohes Darmkrebsrisiko bei hoher Diabetesgefahr

Deshalb impft ein Hamburger Onkologe gegen Corona

Newsletter